1371 related articles for article (PubMed ID: 22918931)
21. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
22. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.
Marr LA; Gilham DE; Campbell JD; Fraser AR
Clin Exp Immunol; 2012 Feb; 167(2):216-25. PubMed ID: 22235997
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic lymphocyte-mediated immunotherapy.
Smyth MJ; Kershaw MH
Aust N Z J Med; 1995 Dec; 25(6):852-8. PubMed ID: 8770363
[TBL] [Abstract][Full Text] [Related]
24. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
25. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
26. Tumour escape: antitumour effectors too much of a good thing?
Pawelec G
Cancer Immunol Immunother; 2004 Mar; 53(3):262-74. PubMed ID: 14685780
[TBL] [Abstract][Full Text] [Related]
27. The blockade of immune checkpoints in cancer immunotherapy.
Pardoll DM
Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
[TBL] [Abstract][Full Text] [Related]
28. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
29. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
31. The role of T lymphocytes in the immunotherapy of tumours.
Brondz BD; Balashov KE
Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
[TBL] [Abstract][Full Text] [Related]
32. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
33. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
34. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy.
Starska-Kowarska K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980527
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
36. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
37. Investigating T Cell Immunity in Cancer: Achievements and Prospects.
Zeng Z; Chew HY; Cruz JG; Leggatt GR; Wells JW
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809369
[TBL] [Abstract][Full Text] [Related]
38. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cells and other innate lymphoid cells in cancer.
Chiossone L; Dumas PY; Vienne M; Vivier E
Nat Rev Immunol; 2018 Nov; 18(11):671-688. PubMed ID: 30209347
[TBL] [Abstract][Full Text] [Related]
40. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
Ochsenbein AF; Sierro S; Odermatt B; Pericin M; Karrer U; Hermans J; Hemmi S; Hengartner H; Zinkernagel RM
Nature; 2001 Jun; 411(6841):1058-64. PubMed ID: 11429607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
